[1] Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature[J]. Can Urol Assoc J, 2018, 12(5):E197-E209. DOI: 10.5489/cuaj.5255.
[2] 李远超,蒙冬如,李文华,等.低能量冲击波与低频TENS治疗顽固性ⅢB型前列腺炎的临床对照研究[J].国际医药卫生导报,2023,29(23):3350-3355. DOI:10.3760/cma.j.issn.1007-1245.2023.23.007.
[3] Cosentino M, Di Nauta M, Boeri L, et al. Conservative treatment of Peyronie's disease: a guide[J]. World J Urol, 2024, 42(1):317. DOI: 10.1007/s00345-024-04975-6.
[4] Fode M, Russo GI, Verze P. Therapeutic areas of Li-ESWT in sexual medicine other than erectile dysfunction[J]. Int J Impot Res, 2019, 31(3):223-230. DOI: 10.1038/s41443-019-0114-2.
[5] Porst H. Review of the current status of low intensity extracorporeal shockwave therapy (Li-ESWT) in erectile dysfunction (ED), Peyronie's disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients[J]. Sex Med Rev, 2021, 9(1):93-122. DOI: 10.1016/j.sxmr.2020.01.006.
[6] Ory J, MacDonald L, Langille G. Noninvasive treatment options for Peyronie's disease[J]. Sex Med Rev, 2020, 8(4):603-614. DOI: 10.1016/j.sxmr.2019.12.002.
[7] Kim J, Drury R, Morenas R, et al. Pathophysiology and grayscale ultrasonography of penile corporal fibrosis[J]. Sex Med Rev, 2022, 10(1):99-107. DOI: 10.1016/j.sxmr.2021.07.005.
[8] Kahl C, Cleland JA. Visual analogue scale, numeric pain rating scale and the McGill Pain Questionnaire: an overview of psychometric properties[J].Physical Therapy Reviews, 2005, 10(2):123-128. DOI:10.1179/108331905X55776.
[9] Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction[J]. Int J Impot Res, 1999, 11(6):319-326. DOI: 10.1038/sj.ijir.3900472.
[10] 李鹏程,陈鑫,朱晓博,等.低能量体外冲击波治疗阴茎硬结症初步探讨(附32例报告)[J].中华男科学杂志,2018,24(4):340-344. DOI:10.13263/j.cnki.nja.2018.04.010.
[11] Chen JY, Hockenberry MS, Lipshultz LI. Objective assessments of Peyronie's disease[J]. Sex Med Rev, 2018, 6(3):438-445. DOI: 10.1016/j.sxmr.2017.12.006.
[12] Hegarty PK, O Sullivan D, Hegarty PA, et al. Multiple plaque incisions with or without grafting for Peyronie's disease[J]. BJUI Compass, 2022, 3(3):220-225. DOI: 10.1002/bco2.130.
[13] El-Khatib FM, Huynh LM, Yafi FA. Intraoperative methods for residual curvature correction during penile prosthesis implantation in patients with Peyronie's disease and refractory erectile dysfunction[J]. Int J Impot Res, 2020, 32(1):43-51. DOI: 10.1038/s41443-019-0215-y.
[14] Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease[J]. J Urol, 2006, 175(6):2115-2118. DOI: 10.1016/S0022-5347(06)00270-9.
[15] Osmonov D, Ragheb A, Ward S, et al. ESSM position statement on surgical treatment of Peyronie's disease[J]. Sex Med, 2022, 10(1):100459. DOI: 10.1016/j.esxm.2021.100459.
[16] Cocci A, Di Maida F, Russo GI, et al. Correction to: efficacy of collagenase clostridium histolyticum (Xiapex®) in patients with the acute phase of Peyronie's disease[J]. Clin Drug Investig, 2021, 41(5):497. DOI: 10.1007/s40261-021-01037-2.
[17] Adeldaeim HM, Abouyoussif T, Gebaly OE, et al. Prognostic indicators for successful low-intensity extracorporeal shock wave therapy treatment of erectile dysfunction[J]. Urology, 2021, 149:133-139. DOI: 10.1016/j.urology.2020.12.019.
[18] Canguven O, Khalafalla K, Al Ansari A. Low-intensity extracorporeal shockwave therapy for erectile dysfunction[J]. Arab J Urol, 2021, 19(3):340-345. DOI: 10.1080/2090598X.2021.1948158.
[19] 莫敦胜,詹绪新,石红卫,等.低能量冲击波治疗勃起功能障碍疗效及安全性:随机对照试验的meta分析[J].中华男科学杂志,2019,25(3):257-264. DOI:10.13263.j.cnki.nja.2019.03.010.
[20] Saitta G, Di Paola G, Mantovani FA, et al. (396) Low intensity - extracorporeal shock wave therapy (LI-ESWT) in the treatment of erectile dysfunction: initial experience and follow up[J]. J Sex Med, 2024, 21 (Supple4): qdae041.015. DOI: 10.1093/jsxmed/qdae041.015.
[21] Wang M, Yang D, Hu Z, et al. Corrigendum: extracorporeal cardiac shock waves therapy improves the function of endothelial progenitor cells after hypoxia injury via activating PI3K/Akt/eNOS signal pathway[J]. Front Cardiovasc Med, 2021, 8:793246. DOI: 10.3389/fcvm.2021.793246.
[22] Li G, Xu X, Man L. Low-intensity extracorporeal shock wave therapy for Peyroniès disease: a systematic review and meta-analysis[J]. BMC Urol, 2024, 24(1):217. DOI: 10.1186/s12894-024-01607-4.
[23] Rubino M, Ricapito A, Finati M, et al. (326) Low-intensity extracorporeal shockwave therapy improves pain in patients with Peyronie's disease[J]. J Sex Med, 2024, 21(Supple4): qdae041.044. DOI: 10.1093/jsxmed/qdae041.044.
[24] Polito M, Cormio A, Galosi AB. (270) Clinical results of low intensity extracorporeal shock wave therapy (LI-ESWT) after 3 years of therapy[J]. J Sex Med, 2024, 21(Supple4): qdae041.024. DOI: 10.1093/jsxmed/qdae041.024.
[25] Liu T, Shindel AW, Lin G, et al. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy[J]. Int J Impot Res, 2019, 31(3):170-176. DOI: 10.1038/s41443-019-0113-3.
[26] Yousif A, Natale C, Hellstrom WJG. Conservative therapy for Peyronie's disease: a contemporary review of the literature[J]. Curr Urol Rep, 2021, 22(2):6. DOI: 10.1007/s11934-020-01024-8.
|